Results 171 to 180 of about 4,730,453 (227)

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, Volume 65, Issue 39, 21 September 2026.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Regional IVIM-DWI Abnormalities in Normal-Appearing White Matter and Lesion Tissue in Relapsing-Remitting Multiple Sclerosis. [PDF]

J Clin Med
Alomair OI, Alghamdi SA.
europepmc   +1 more source

Correlation Is Not Prediction: Reassessing Predictive MRI Evidence in Guidelines for Persons With Relapsing-Remitting Multiple Sclerosis. [PDF]

J Cent Nerv Syst Dis
Minas D, Buchka S, Havla J, Mansmann U.
europepmc   +1 more source

Identification of diagnostic biomarkers for relapsing-remitting multiple sclerosis in plasma by mass spectrometry-based proteomics. [PDF]

J Neuropathol Exp Neurol
García-Silva VM, Chicano-Galvez E, García-Sánchez MI, Peralbo-Molina Á, Hernández-Valladares M.   +4 more
europepmc   +1 more source

Strategies for integrating artificial intelligence and cognitive assessment to predict disability progression in relapsing-remitting multiple sclerosis: A model development study. [PDF]

PLOS Digit Health
Zhu C, Zhang X, van der Walt A, Taylor B, Monif M, Kalincik T, Lechner-Scott J, Buzzard K, Kilpatrick T, Barnett M, Zhou Z, Jokubaitis V, Gresle M, Darby D, Mehta D, Ge Z, Butzkueven H, Merlo D.   +17 more
europepmc   +1 more source

Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort. [PDF]

J Neurol
Filippi M, D'Amico E, Brescia Morra V, Zanetta C, Zanghì A, Di Filippo PS, Longobardi E, Colombo E, Mirabella M, Conte A, Tomassini V, Masini C, Perosino V, Tortorella P, Rocca MA, MUPSO Study Group.   +15 more
europepmc   +1 more source

A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple Sclerosis. [PDF]

Neurol Ther
Veyrier CA, Vermersch P, Casez O, Heinzlef O, Payet M, Luciani L, Collongues N, Duracinsky M.   +7 more
europepmc   +1 more source

Cross-sectional brain volumetric measures and disability outcomes in relapsing-remitting multiple sclerosis. [PDF]

J Neurol
Hayes MTG, Beadnall HN, Merlo D, Monif M, Zhu C, Barnett M, Buzzard K, Horakova D, Kalincik T, Laureys G, Lui E, Lechner-Scott J, Nguyen AL, Patti F, Sima DM, Smeets D, Vaneckova M, Van Hecke W, Van Pesch V, van der Walt A, Butzkueven H.   +20 more
europepmc   +1 more source

Investigating Depression and MRI Associations in Middle Eastern Relapsing-Remitting Multiple Sclerosis. [PDF]

J Biomed Phys Eng
Pishdad P, Zeinali-Rafsanjani B, Poursadeghfard M, Kalaee M, Ostovarfar J, Salehi A.   +5 more
europepmc   +1 more source

From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis. [PDF]

J Clin Med
Yaşargün DÖ, Türkoğlu R.
europepmc   +1 more source